AU · rank #9 · 2026-07-20
GH
NASDAQ · $20.67B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.307 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.10 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $78,456 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $171.08 | +9.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +13.63% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.70 |
| Gross margin TTM | +64.9% |
| 52w high | $174.08 |
| Market cap (USD) | $20.67B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Guardant Health is a liquid biopsy and cancer screening company whose three franchises—oncology diagnostics, biopharma/data services, and Shield colorectal cancer screening—generated over $1 billion in trailing 12-month revenue with 48% Q1 2026 growth.
Rationale
The analyst_upside signal is reinforced by 10 target raises in 30 days, a strong 4.70/5 buy-side rating from 18 analysts, 75% revision agreement, and accelerating momentum (+13.6%) tied to concrete fundamental catalysts—raised guidance, Shield volume inflection, and NovaSeq X margin expansion—rather than pure sentiment rotation.
Material risks
- 1Reimbursement and guideline dependency is the primary thesis-breaker—Shield's volume ramp from ~44,000 tests is contingent on ACS guideline inclusion and sustained Medicare coverage, and a delay or unfavorable ruling would materially collapse the screening growth narrative underpinning most of the analyst target raises.
- 2Persistent free-cash-flow burn of ~$185–195M guided for 2026 with breakeven not expected until end-2027 means any revenue or margin miss forces dilutive capital raises, directly pressuring the share price and undermining the analyst upside thesis.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.